Detalhe da pesquisa
1.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652354
2.
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study.
Hepatology
; 77(3): 760-773, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36152015
3.
Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers.
Hepatology
; 75(1): 43-58, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407567
4.
Changes in Prescribing Patterns in Stage III Colon Cancer.
J Natl Compr Canc Netw
; 21(8): 841-850.e4, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549913
5.
The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis.
Oncologist
; 27(12): 1034-1040, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239399
6.
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
Clin Gastroenterol Hepatol
; 20(3): e508-e528, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857637
7.
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
Invest New Drugs
; 40(1): 134-141, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463891
8.
Utility of geriatric assessments in evaluation of older adults for kidney transplantation.
Clin Transplant
; 36(12): e14813, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124434
9.
Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma.
Future Oncol
; 18(30): 3419-3433, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098270
10.
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations.
Dig Dis Sci
; 67(8): 3797-3805, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34773565
11.
Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
Semin Liver Dis
; 41(2): 136-141, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33957697
12.
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer.
Oncologist
; 26(8): 668-675, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33631043
13.
Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Oncologist
; 26(7): 569-578, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33555095
14.
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Oncologist
; 26(7): 610-618, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604969
15.
ABHD10 is an S-depalmitoylase affecting redox homeostasis through peroxiredoxin-5.
Nat Chem Biol
; 15(12): 1232-1240, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31740833
16.
Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.
Oncologist
; 25(8): e1246-e1248, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510802
17.
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Oncologist
; 25(5): 380-e763, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826977
18.
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Lancet Oncol
; 20(8): 1070-1082, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31262657
19.
Pathway-Specific Asymmetries between ON and OFF Visual Signals.
J Neurosci
; 38(45): 9728-9740, 2018 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249795
20.
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Oncologist
; 24(9): 1174-1179, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31164455